The panel could refuse funding if the benefits of a study are not considered important enough to outweigh the risks to public health; if the results could be obtained in a safer way; or if the researchers have not demonstrated an ability to do the work safely and securely.
Identifying benefits of a study Researchers emphasized the importance of framing a discussion of study benefits to include personal benefits to help participants become more motivated about enrolling in a study.
Facilitators to enhance recruitment practices included accommodating participants outside of regular clinic hours, incentivizing participants, cultivating relationships with communities, schools and clinics prior to study recruitment, emphasizing benefits of a study for the patient, and shifting language to focus on health rather than obesity.
Finally, the absolute difference in risk is another statistical factor to consider when potential benefits of a study drug are being assessed.
Employing FWs from a community can in itself be described as part of the indirect benefits of a study for communities, and can facilitate mutual understanding between research centres and their communities [ 13– 15].
Most borderline patients, except if in a brief psychotic episode when under severe stress, have normal cognitive function, and will be able to comprehend and speak about the risks and benefits of a study.
Recent literature on recruitment has highlighted the need to sell the benefits of a study to the practice or physicians, and not just the merits of the research [ 10, 19].
A further issue is the extent to which the risks and benefits of a study can be determined without recourse to the potential participants' own views on the study – the point being that different aspects of a study may pose different ethical, religious or personal concerns for different participants.
However, the benefit of a cohort study is the possibility to study factors that might be important in the context such in present study.
Weijer and Miller, for example, made it necessary for RECs to always consider therapeutic warrant, equipoise, and minimal risk when evaluating the risk-benefit balance of a study.
